Phase II study of TLK286 [canfosfamide; TELCYTA; Telik] for the treatment of advanced non-small cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2013
At a glance
- Drugs Canfosfamide (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Dec 2009 Actual end date (Aug 2002) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2007 Clinical hold removed by FDA - status changed from suspended to in progress.